Drugs / HPV-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05895370 | Apr 2023 → Dec 2024 | neoplasm | BGI, China | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05895370 ↗ |
| Modality | Cell therapy | “HPV-T cells will be cultured from mononuclear cells collected from participant's peripheral blood in the laboratory and they will be given back to the participant intravenously.” NCT05895370 ↗ |
| Route | Intravenous | “they will be given back to the participant intravenously.” NCT05895370 ↗ |